Key PointsQuestionDo anti–programmed cell death 1 and anti–programmed cell death ligand 1 deliver different clinical outcomes? FindingsIn this systematic review and meta-analysis of 19 randomized clinical trials involving 11 379 patients, anti–programmed cell death 1 appears to exhibit significantly greater overall survival compared with anti–programmed cell death ligand 1 with a comparable safety profile in patients with solid tumors. MeaningAnti–programmed cell death 1 appears to exhibit favorable survival outcomes and a comparable safety profile with anti–programmed cell death ligand 1 in cancer therapy, which may provide valuable insight for future treatment strategy.
JAMA Oncology – American Medical Association
Published: Mar 26, 2020